Ras-related C3 botulinum toxin substrate 2 (RAC2) (RAC2)

Ras-related C3 botulinum toxin substrate 2 (RAC2) is a small signaling G protein belonging to the Rho family of GTPases, primarily expressed in hematopoietic cells such as neutrophils, macrophages, and lymphocytes (UniProt, GeneCards). It functions as a molecular switch, cycling between an inactive GDP-bound state and an active GTP-bound state to regulate critical cellular processes including actin cytoskeleton reorganization, chemotaxis, and the production of reactive oxygen species (ROS) via the NADPH oxidase complex (PubMed, NIH). In the context of disease, RAC2 is implicated in various hematologic malignancies and solid tumors, where its overexpression or hyperactivation promotes cell proliferation, invasion, and therapy resistance (ResearchGate, MDPI). Conversely, loss-of-function or dominant-negative mutations in RAC2 lead to severe primary immunodeficiencies characterized by defective neutrophil function and recurrent infections (PubMed, NIH). Therapeutic strategies targeting RAC2 involve small-molecule inhibitors that disrupt its interaction with guanine nucleotide exchange factors (GEFs) or prevent GTP binding, offering potential treatments for cancer and autoinflammatory conditions (ACS, MDPI). Additionally, RAC2 has been identified as a prognostic biomarker in several cancers, including renal cell carcinoma and breast cancer, where its expression levels correlate with patient outcomes and immune infiltration (PubMed, NIH).

Other names

p21-Rac2EN-7Ras-related C3 botulinum toxin substrate 2Small G protein Rac2

Inhibition of GTP binding, inhibition of GEF interaction, and modulation of the GTPase catalytic cycle.